EGFR and lung cancer: Compared with stage-IIIB/IV lung cancer patients with pan-negative driver mutations (OS 12.3 months), those with mutations of EGFR (OS 22.5 months) or ALK (OS 21.9 months) experienced better OS; while KRAS mutations (OS 6.4 months) were associated with poor OS.